Mannose-binding lectin (MBL) and vascular complications in diabetes

Hormone and Metabolic Research

Volumn 37, Issue SUPPL. 1, 2005, Pages

  Hansen, T K ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Complement; Diabetic nephropathy; Mannose binding lectin; MBL; Type 1 diabetes

Indexed keywords

CARBOHYDRATE; MANNOSE BINDING LECTIN; PLASMA PROTEIN;

CARDIOVASCULAR DISEASE; CELL DAMAGE; CHROMOSOME 10; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEREDITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; VASCULAR DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; COMPLEMENT SYSTEM PROTEINS; DIABETES COMPLICATIONS; HUMANS; MANNOSE-BINDING LECTIN;

EID: 20444470135     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-861372     Document Type: Conference Paper

References (48)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066
2. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-1144
3. Thiel S, Reid KB. Structures and functions associated with the group of mammalian lectins containing collagen-like sequences. FEBS Lett 1989; 250: 78-84
4. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol 2001; 38: 133-149
5. Hansen TK, Thiel S, Wouters PJ et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88: 1082-1088
6. Steffensen R, Thiel S, Varming K et al. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000; 241: 33-42
7. Hansen TK, Thiel S, Dall R et al. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-1 independent immunomodulatory effect of GH. J Clin Endocrinol Metab 2001; 86: 5383-5388
8. Nielsen SL, Andersen PL, Koch C et al. The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. Clin Exp Immunol 1995; 100: 219-222
9. Hansen TK, Tarnow L, Thiel S et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004; 53: 1570-1576
10. Naito H, Ikeda A, Hasegawa K et al. Characterization of human serum mannan-binding protein promoter. J Biochem (Tokyo) 1999; 126: 1004-1012
11. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996; 17: 532-540
12. Thiel S, Vorup-Jensen T, Stover CM et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997; 386: 506-510
13. Neth O, Jack DL, Dodds AW et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68: 688-693
14. Super M, Thiel S, Lu J et al. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989; 2: 1236-1239
15. Summerfield JA, Ryder S, Sumiya M et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995; 345: 886-889
16. Summerfield JA, Sumiya M, Levin M et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314: 1229-1232
17. Garred P, Madsen HO, Hofmann B et al. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995; 346: 941-943
18. Garred P, Madsen HO, Balslev U et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349: 236-240
19. Garred P, Pressler T, Madsen HO et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104: 431-437
20. Koch A, Melbye M, Sorensen P et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001; 285: 1316-1321
21. Peterslund NA, Koch C, Jensenius JC et al. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358: 637-638
22. Neth O, Hann I, Turner MW et al. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001; 358: 614-618
23. Garred P, Strom J, Quist L et al. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003; 188: 1394-1403
24. Fidler KJ, Wilson P, Davies JC et al. Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med. 2004; 30: 1438-1445
25. Turner MW, Hamvas RM. Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2000; 2: 305-322
26. Kilpatrick DC. Mannan-binding lectin and its role in innate immunity. Transfus Med 2002; 12: 335-352
27. Lipscombe RJ, Sumiya M, Hill AV et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene [published erratum appears in Hum Mol Genet 1993 Mar; 2(3): 342]. Hum Mol Genet 1992; 1: 709-715
28. Malhotra R, Wormald MR, Rudd PM et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1: 237-243
29. Collard CD, Lekowski R, Jordan JE et al. Complement activation following oxidative stress. Mol Immunol 1999; 36: 941-948
30. Collard CD, Vakeva A, Morrissey MA et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000; 156: 1549-1556
31. Collard CD, Montalto MC, Reenstra WR et al. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001; 159: 1045-1054
32. Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001; 104: 1413-1418
33. Granger CB, Mahaffey KW, Weaver WD et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190
34. Schalkwijk CG, Poland DC, van Dijk W et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-357
35. Jager A, van Hinsbergh VW, Kostense PJ et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler. Thromb Vasc Biol 1999; 19: 3071-3078
36. Mogensen CE. Genetics and Diabetic Renal Disease - Still a Big Black Hole. Diabetes Care 2003; 26: 1631-1632
37. Seaquist ER, Goetz FC, Rich S et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165
38. Acosta J, Hettinga J, Fluckiger R et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000; 97: 5450-5455
39. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 2003; 14: S186-S191
40. Uesugi N, Sakata N, Nangaku M et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation. Am J Kidney Dis 2004; 44: 224-238
41. Endo M, Ohi H, Ohsawa I et al. Complement activation through the lectin pathway in patients with Henoch-Schonlein purpura nephritis. Am J Kidney Dis 2000; 35: 401-407
42. Endo M, Ohi H, Ohsawa I et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998; 13: 1984-1990
43. de Vries B, Walter SJ, Peutz-Kootstra CJ et al. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004; 165: 1677-1688
44. Hansen TK, Thiel S, Knudsen ST et al. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 4857-4861
45. Saraheimo M, Forsblom C, Hansen TK et al. Increased levels of mannan-binding lectin (MBL) in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2005; 48: 198-202
46. Fiane AE, Videm V, Lingaas PS et al. Mechanism of Complement Activation and Its Role in the Inflammatory Response After Thoracoabdominal Aortic Aneurysm Repair. Circulation 2003; 108: 849-856
47. Mathew V, Gersh BJ, Williams BA et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-480
48. Hovind P, Hansen T, Tarnow L et al. Mannose-Binding Lectin as a predictor of microalbuminuria in type 1 diabetes - An inception cohort study. Diabetes 2005; 54: 1523-1527